Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action. This anticancer agent should be considered a pro-drug, whose pharmacological efficiency and/or genotoxic side effects are dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation to species forming covalent DNA adducts. Ellipticine can also act as an inhibitor or inducer of biotransformation enzymes, thereby modulating its own metabolism leading to its genotoxic and pharmacological effects. Here, a comparison of the toxicity of ellipticine to human breast adenocarcinoma MCF-7 cells, leukemia HL-60 and CCRF-CEM cells, neuroblastoma IMR-32, UKF-NB-3 and UKF-NB-4 cells and U87MG glioblastoma cells and mechanisms of its action to these cells were evaluated. Treatment of all cells tested with ellipticine resulted in inhibition of cell growth and proliferation. This effect was associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by 13-hydroxy- and 12-hydroxyellipticine, the ellipticine metabolites generated by CYP and peroxidase enzymes, in MCF-7, HL-60, CCRF-CEM, UKF-NB-3, UKF-NB-4 and U87MG cells, but not in neuroblastoma UKF-NB-3 cells. Therefore, DNA adduct formation in most cancer cell lines tested in this comparative study might be the predominant cause of their sensitivity to ellipticine treatment, whereas other mechanisms of ellipticine action also contribute to its cytotoxicity to neuroblastoma UKF-NB-3 cells.

Department of Biochemistry Faculty of Science Charles University Prague Czech Republic

Zobrazit více v PubMed

Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudeček J, Václavíková R, Frei E. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos. 2007;35:1926–1934. PubMed

Auclair C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys. 1987;259:1–14. PubMed

Bořek-Dohalská L, Frei E, Stiborová M. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun. 2004;69:603–615.

Cinatl J, Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, Schwabe D. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-Cancer Drugs. 1997;8:958–63. PubMed

Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol. 2002;64:289–295. PubMed

Garbett NC, Graves DE. Extenting nature's leads: the anticancer agent ellipticine. Curr Med Chem Anti-Cancer Agents. 2004;4:149–72. PubMed

Huska D, Adam V, Krizkova S, Hrabeta J, Eckschlager T, Stiborova M, Kizek R. An electrochemical study of interaction of an anticancer alkaloid ellipticine with DNA. Chim Oggi-Chem Today. 2010a;28(5) Suppl S:15–17.

Huska D, Adam V, Hubalek J, Trnkova L, Eckschlager T, Stiborova M, Provaznik I, Kizek R. Off-line coupling of automated pipetting system with square wave voltammetry as a tool for study of drug-DNA interaction. Chim Oggi-Chem Today. 2010b;28(5) Suppl S:18–20.

Fossé P, René B, Charra M, Paoletti C, Saucier JM. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol. 1992;42:590–595. PubMed

Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem. 1995;270:4998–5004. PubMed

Kuo PL, Hsu YL, Chang CH, Lin CC. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 2005a;223:293–301. PubMed

Kuo PL, Hsu YL, Kuo YC, Chang CH, Lin CC. The antiproliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs. 2005b;16:789–795. PubMed

Kuo PL, Kuo YC, Hsu YL, Cho CY, Lin CC. Ellipticine induced apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 2006;78:2550–2557. PubMed

Martinkova E, Dontenwill M, Frei E, Stiborova M. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett. 2009;30(Suppl 1):60–66. PubMed

Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K, Martin S, Dontenwill M. α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer. 2010;127:1240–1248. PubMed

McCormick DL, Adamowski CB, Fiks A, Moon RC. Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res. 1981;41:1690–1694. PubMed

Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J, Jr, Fermandjian S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem. 1991;25:1820–1829. PubMed

Moserová M, Kotrbová V, Rupertová M, Naiman K, Hudeček J, Hodek P, Frei E, Stiborová M. Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett. 2008;29:728–732. PubMed

Ohashi M, Sugikawa E, Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res. 1995;86:819–829. PubMed PMC

Poljaková J, Dračínský M, Frei E, Hudeček J, Stiborová M. The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect Czech Chem Commu. 2006;71:1169–1185.

Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hraběta J, Stiborová M. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 2007;252:270–279. PubMed

Poljaková J, Eckschlager T, Hraběta J, Hřebačková J, Smutný S, Frei E, Martínek V, Kizek R, Stiborová M. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol. 2009;77:1466–1479. PubMed

Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL, Lown JW. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry. 1994;33:10271–10285. PubMed

Stiborová M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 2001;62:675–684. PubMed

Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer. 2003a;107:885–890. PubMed

Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol. 2003b;16:38–47. PubMed

Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res. 2004;64:8374–8380. PubMed

Stiborová M, Rupertová M, Schmeiser HH, Frei E. Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006;150:13–23. PubMed

Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T, Frei E. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer. 2007a;120:243–251. PubMed

Stiborová M, Rupertová M, Aimová D, Ryšlavá H, Frei E. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology. 2007b;236:50–60. PubMed

Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH, Frei E. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol. 2008;226:318–327. PubMed

Stiborová M, Rupertová M, Frei E. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta. 2011;1814:175–185. PubMed

Sugikawa E, Hosoi T, Yazaki N, Gamanuma N, Nakanishi N, Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 1999;19:3099–3108. PubMed

Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy